Vera Therapeutics slips on earnings miss as FDA review looms
Biotech firm reports wider loss but maintains strong cash runway ahead of July 2026 atacicept approval decision
Vera Therapeutics shares dipped 1.6% to $41.68 on Thursday after the clinical-stage biotechnology company reported full-year 2025 financial results that showed widening losses, though investors appeared focused on the company's advancing pipeline rather than near-term profitability.
The company, which is developing treatments for serious immune diseases, reported a net loss of $299.6 million for fiscal 2025, double the previous year's figure. Earnings per share missed analyst expectations significantly, coming in at negative $4.66 compared to the consensus estimate of negative $1.13, according to the company's business update.
Despite the headline miss, the modest stock decline suggests investors are looking past the losses to a potentially transformative year ahead. Vera ended 2025 with $714.6 million in cash and recently completed an $800 million financing, providing what analysts consider sufficient runway to reach commercial launch of its lead candidate atacicept.
The primary focus for investors remains the U.S. Food and Drug Administration's review of atacicept, a treatment for IgA nephropathy (IgAN), a progressive kidney disease with limited treatment options. The FDA granted Priority Review to Vera's Biologics License Application (BLA) in January, setting a target action date of July 7, 2026.
The application is supported by data from the pivotal Phase 3 ORIGIN 3 trial, which met its primary endpoint by demonstrating a 46% reduction from baseline in proteinuria at week 36 for participants treated with atacicept, compared to a 42% reduction versus placebo. The treatment also showed improvements in secondary endpoints, including reductions in galactose-deficient IgA1 and resolution of hematuria.
If approved, atacicept would be the first B-cell modulator targeting both B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) for IgAN, and would be administered as a once-weekly, subcutaneous autoinjector for at-home use, according to company filings.
Analysts have maintained a broadly positive outlook on the stock despite the earnings shortfall. The consensus target price stands at $75.15, representing roughly 80% upside from current levels, with 12 analysts rating the stock a Buy or Strong Buy and just two at Hold, according to market data.
The company is planning for a mid-2026 commercial launch of atacicept, contingent upon FDA approval. The ORIGIN 3 trial remains ongoing, with completion expected in 2027, when it will evaluate long-term kidney outcomes including estimated glomerular filtration rate (eGFR).
Vera Therapeutics, headquartered in South San Francisco, California, has seen its shares trade in a 52-week range of $18.53 to $56.05, giving the company a market capitalization of approximately $3 billion. Institutional ownership stands at 116.6%, indicating significant interest from large investors despite the stock's volatility.
The July 7 PDUFA date represents the next major catalyst for the company, with investors watching for any signals from the FDA regarding the regulatory review process. Priority review designation typically shortens the review timeline from the standard 10 months to six months, reflecting the agency's assessment that if approved, the drug would provide significant improvements in the treatment of a serious condition.